Navigation Links
Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
Date:4/20/2011

PLYMOUTH, Mass., April 20, 2011 /PRNewswire/ -- Harvest Technologies Corp. (www.harvesttech.com) announced today that the first twelve patients of its sixty patient Heart Failure trial have been enrolled at Medanta-the Medicity in Gurgaon INDIA.

The trial is intended to evaluate the safety and clinical effect of Harvest's BMAC autologous cell composition to treat patients with Congestive Heart Failure (CHF) when using a minimally invasive retrograde coronary sinus delivery.  This is a randomized, controlled design treating both ischemic and non-ischemic heart failure patients.  Patient enrollment will take place in sites in India, Germany and Peru and will feature electronic data entry with its data coordinating center at the University of Utah. The overall trial will be directed by Amit Patel, MD, Director, Center for Cardiac Cell Therapy at the University of Utah. The trial is being conducted in compliance with the United States FDA clinical trial regulations, ICH GCP, local IRB or IEC regulations and the "Declaration of Helsinki" and a Data Safety Monitoring Board (DSMB) will monitor adverse events.  

Congestive Heart Failure is a persistent and relentless problem, which affects over an estimated 20 million patients world-wide. It occurs when the heart's ability to pump blood is so impaired that "systemic perfusion is inadequate to meet the body's demands" and this condition cannot be mediated by either by medication or surgical or endovascular intervention. A major advance in treatment is needed which could reverse this condition and in ischemic patients initiate neovascularization to restore perfusion within the affected area of the myocardium.

While there are several cardiac trials that have shown a clinical effect arising from the delivery of bone marrow cells through the coronaries, this approach offers several advantages according to Dr. Patel. "This novel delivery approach has several advantages over the antigrade approach. It is a safer approach into the heart, allows for the delivery of significantly more cells and in our experience results in substantially greater cell retention. In addition, the Harvest rapid processing of bone marrow in the procedure room could allow the procedure to be done on an outpatient basis."

"Congestive Heart Failure is a cruel, debilitating disease effecting over 20 million people. Although many of the cell therapy studies have demonstrated promise, the improvements shown have been less than ideal. We are extremely optimistic that this study will show the improvement in clinical results that can eventually lead to a treatment option for this patient population," states Gary Tureski, President Harvest Technologies.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Contact:

P. Kevin Benoit; VP / General Manager Strategic Business Development – 508-732-7500


'/>"/>
SOURCE Harvest Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nanonets give rust a boost as agent in water splittings hydrogen harvest
2. Scientists produce transparent, light-harvesting material
3. Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs
4. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
5. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
6. UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year
7. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
8. Scientists determine the structure of highly efficient light-harvesting molecules in green bacteria
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
11. Life Technologies to Present at Bairds 2011 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... Hill, CT (PRWEB) , ... June 20, 2017 ... ... support, today announced that the CTNext board of directors has formed a Higher ... by a working group composed of institution presidents and other high-ranking representatives from ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadyl™, ...
(Date:6/20/2017)... ... June 20, 2017 , ... GigaGen Inc ., ... immune repertoires, announces launch of its new Surge(TM) Discovery service at ... of GigaGen, will present on Surge at the conference. , Surge is the ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been ... One of the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today ... is Kati Abraham , who is well known in the industry and brings ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):